Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X
Abstract
The authors report five elderly men with the fragile X premutation who had a progressive action tremor associated with executive function deficits and generalized brain atrophy. These individuals had elevated fragile X mental retardation 1 gene (FMR1) messenger RNA and normal or borderline levels of FMR1 protein. The authors propose that elevations of FMR1 messenger RNA may be causative for a neurodegenerative syndrome in a subgroup of elderly men with the FMR1 premutation.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Hagerman RJ. Fragile X syndrome. In: Neurodevelopmental disorders: diagnosis and treatment. New York: Oxford University Press, 1999: 61–132.
2.
Rousseau F, Rouillard P, Morel ML, et al. Prevalence of carriers of premutation-size alleles of the FMRI gene, and implications for the population genetics of the fragile X syndrome. Am J Hum Genet . 1995; 57: 1006–1018.
3.
Riddle JE, Cheema A, Sobesky WE, et al. Phenotypic involvement in females with the FMR1 gene mutation. Am J Ment Retard . 1998; 102: 590–601.
4.
Franke P, Leboyer M, Gansicke M, et al. Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res . 1998; 80: 113–127.
5.
Tassone F, Hagerman RJ, Taylor AK, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet . 2000; 91: 144–152.
6.
Hagerman RJ, Staley LW, O’Connor R, et al. Learning-disabled males with a fragile X CGG expansion in the upper premutation size range. Pediatrics . 1996; 97: 122–126.
7.
Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study— preliminary data. Am J Med Genet . 1999; 83: 322–325.
8.
Tassone F, Hagerman RJ, Taylor AK, et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in fragile X syndrome. Am J Hum Genet . 2000; 66: 6–15.
9.
Hills JL, Wilson R, Sobesky W, et al. Executive functioning deficits in adult males with the fragile X permutation. Presented at the 7th International Fragile X Foundation Conference; July 19–22, 2000. Los Angeles, CA.
10.
Waring JD, Korueluk RG. Genetic studies of the myotonic dystrophy CTG repeat. In: Wells RD, Warren ST, eds. Genetic instabilities and heredity neurological diseases. New York: Academic Press; 1998: 131–146.
Information & Authors
Information
Published In
Copyright
© 2001.
Publication History
Received: September 18, 2000
Accepted: March 4, 2001
Published online: July 10, 2001
Published in print: July 10, 2001
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Native functions of short tandem repeats, eLife, 12, (2023).https://doi.org/10.7554/eLife.84043
- A Case of Fragile-X-Associated Tremor/Ataxia Syndrome Without Tremor, Journal of Clinical Neurology, 19, 5, (498), (2023).https://doi.org/10.3988/jcn.2023.0154
- Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review, Pharmaceutics, 15, 6, (1626), (2023).https://doi.org/10.3390/pharmaceutics15061626
- Defining the 3′Epigenetic Boundary of the FMR1 Promoter and Its Loss in Individuals with Fragile X Syndrome, International Journal of Molecular Sciences, 24, 13, (10712), (2023).https://doi.org/10.3390/ijms241310712
- Open-Label Sulforaphane Trial in FMR1 Premutation Carriers with Fragile-X-Associated Tremor and Ataxia Syndrome (FXTAS), Cells, 12, 24, (2773), (2023).https://doi.org/10.3390/cells12242773
- Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on FMR1 Premutation, Cells, 12, 18, (2330), (2023).https://doi.org/10.3390/cells12182330
- A Postmortem MRI Study of Cerebrovascular Disease and Iron Content at End-Stage of Fragile X-Associated Tremor/Ataxia Syndrome, Cells, 12, 14, (1898), (2023).https://doi.org/10.3390/cells12141898
- Phase separation and pathologic transitions of RNP condensates in neurons: implications for amyotrophic lateral sclerosis, frontotemporal dementia and other neurodegenerative disorders, Frontiers in Molecular Neuroscience, 16, (2023).https://doi.org/10.3389/fnmol.2023.1242925
- Sensorimotor and inhibitory control in aging FMR1 premutation carriers, Frontiers in Human Neuroscience, 17, (2023).https://doi.org/10.3389/fnhum.2023.1271158
- Digital gait markers to potentially distinguish fragile X-associated tremor/ataxia syndrome, Parkinson’s disease, and essential tremor, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1308698
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.
Dear Editor:
We are aware of the Desai [1] study of a man with fragile X syndrome (FXS) who also had ALS. This case appears to be the coincidental occurrence of ALS in a patient with FXS. Previous neuropathological reports in FXS have shown limited neuronal cell loss and gliosis [2], although neuronal cell death in the substantia nigra has not previously been reported in FXS. There is evidence, however, of shrinkage of the temporal lobes and dilation of the ventricles with age that is more remarkable in FXS compared to what is seen in controls [3]. Further neuroanatomical studies in those with the full mutation and those with the premutation are needed.
There are no reports of neurodegeneration in patients with the full FXS with ALS other than the case reported by Desai [1]. In contrast, the neurological syndrome in older men with the premutation that we reported [4] has been observed in other cases. We have since seen this tremor ataxia syndrome in nine other men and have the medical records on an additional eight cases who died after a neurodegenerative course. Further epidemiology studies are needed to clarify the prevalence of this problem in both men and women with the premutation. It is unclear whether this condition is related to the elevated mRNA in these males but studies are in progress. The neuropathology in this tremor/ataxia syndrome are also being examined. There is no megalencephaly or loss of neurons in the substantia nigra, indicating a different mechanism of pathogenesis than what was reported or discussed by Munoz.
References:
1. Desai HB,Donat J, Shokeir MH, Munoz DG. Amyotrophic lateral sclerosis in a patient with fragile X syndrome. Neurology 1990; 40:378-80. 2.
Sabaratnam M. Pathological and neuropathological findings in two males with fragile X syndrome. J Intell Disabil Res 2000; 44:81-85.
3. Reiss AL, Abrams MT, Greenlaw R, Freund L, Denckla MB. Neurodevelopmental effects of the FMR-1 full mutation in humans. Nature Medicine 1995; 1:159-67.
4. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57:127- 130.
Hagerman et al have described a syndrome characterized by intention tremor, parkinsonism, executive function disturbances, and generalized brain atrophy in male carriers of the fragile X syndrome [1]. Autopsies were not available. It may be of interest to consider a previous report of a progressive neurodegenerative disease of adult onset in a patient with the characteristic fragile X phenotype and cytogenetically proven fragile X chromosome. At age 39 this man developed dysarthria and spasticity, and by age 40 he was anarthic and unable to stand. In addition to muscle atrophy, fasciculations, increased tone and hyperreflexia, examination showed focal and generalized myoclonic jerks. There was generalized slowing on EEG and cerebral atrophy on CT scan. Autopsy, obtained after death at age 41, showed typical features of amyotrophic lateral sclerosis (ALS), along with megalencephaly (1850 g), evidence of neuronal death in the substantia nigra, and loss of small neurons and gliosis in the neostriatum . Clinical and pathological diagnosis was ALS with atypical features [2]. Thus, both male carriers and patients expressing the full fragile X syndrome can develop neurodegenerative diseases as adults and those diseases may not fit neatly into established categories. By analogy with the fragile X patient, it can be predicted that histological examination of the brains of the fragile X carriers reported by Hagerman et al. will show neuronal loss and gliosis in the absence of beta-amyloid, tau, or alpha-synuclein deposition. This raises questions concerning shared pathogenetic mechanisms among the several neurodegenerative diseases and the role of elevated FMR1 messenger RNA in their development.
Reference List
1. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57:127-130.
2. Desai HB, Donat J, Shokeir MH, Munoz DG. Amyotrophic lateral sclerosis in a patient with fragile X syndrome. Neurology 1990; 40:378- 380.